18 results on '"Kristensen, Søren L."'
Search Results
2. Association of carpal tunnel syndrome with incident diabetes
- Author
-
Jacobsen, Jeppe Ravn, primary, Westergaard, Lucas Malta, additional, Fosbøl, Emil L., additional, Kristensen, Søren L., additional, Køber, Lars, additional, Persson, Frederik, additional, Rossing, Peter, additional, and Rørth, Rasmus, additional
- Published
- 2024
- Full Text
- View/download PDF
3. The effect of sodium‐glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies
- Author
-
Krogh, Jesper, primary, Hjorthøj, Carsten, additional, Kristensen, Søren L., additional, Selmer, Christian, additional, and Haugaard, Steen B., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end‐stage renal disease
- Author
-
Malik, Mariam E., primary, Madelaire, Christian, additional, D'Souza, Maria, additional, Blanche, Paul, additional, Kristensen, Søren L., additional, Kistorp, Caroline, additional, Gustafsson, Finn, additional, Køber, Lars, additional, Rørth, Rasmus, additional, McMurray, John, additional, Sattar, Naveed, additional, Gislason, Gunnar, additional, Torp‐Pedersen, Christian, additional, and Schou, Morten, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure
- Author
-
Rørth, Rasmus, Fosbøl, Emil L., Mogensen, Ulrik M., Kragholm, Kristian, Numé, Anna-karin, Gislason, Gunnar H, Jhund, Pardeep S., Petrie, Mark C., McMurray, John J.V., Torp-Pedersen, Christian, Køber, Lars, and Kristensen, Søren L.
- Abstract
Background: Employment status at time of first heart failure (HF) hospitalization may be an indicator of both self-perceived and objective health status. In this study, we examined the association between employment status and the risk of all-cause mortality and recurrent HF hospitalization in a nationwide cohort of patients with HF. \ud Methods and Results: We identified all patients of working age (18-60 years) with a first HF hospitalisation in the period 1997-2015 in Denmark, categorized according to whether or not they were part of the workforce at time of the index admission. The primary outcome was death from any cause and the secondary outcome was readmission for HF. Cumulative incidence curves, binomial regression and Cox regression models were used to assess outcomes. Of 25571 patients with a first hospitalization for HF, 15428 (60%) were part of the workforce at baseline. Patients in the workforce were significantly younger (53 vs. 55 years) more likely to be male (75% vs 64%) and less likely to have diabetes (13% vs 22%) and chronic obstructive pulmonary disease (5% vs 10%), all p-values
- Published
- 2018
6. Individualizing surgical revascularization in patients with ischaemic heart failure — a further dive into STICHES
- Author
-
Kristensen, Søren L., primary
- Published
- 2019
- Full Text
- View/download PDF
7. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
- Author
-
Rørth, Rasmus, primary, Jhund, Pardeep S., additional, Kristensen, Søren L., additional, Desai, Akshay S., additional, Køber, Lars, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Zile, Michael R., additional, Packer, Milton, additional, and McMurray, John J.V., additional
- Published
- 2018
- Full Text
- View/download PDF
8. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure
- Author
-
Rørth, Rasmus, primary, Fosbøl, Emil L., additional, Mogensen, Ulrik M., additional, Kragholm, Kristian, additional, Numé, Anna‐karin, additional, Gislason, Gunnar H., additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, McMurray, John J.V., additional, Torp‐Pedersen, Christian, additional, Køber, Lars, additional, and Kristensen, Søren L., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial
- Author
-
Kristensen, Søren L., primary, Mogensen, Ulrik M., additional, Tarnesby, Georgia, additional, Gimpelewicz, Claudio R., additional, Ali, Mohammed A., additional, Shao, Qing, additional, Chiang, YannTong, additional, Jhund, Pardeep S., additional, Abraham, William T., additional, Dickstein, Kenneth, additional, McMurray, John J.V., additional, and Køber, Lars, additional
- Published
- 2017
- Full Text
- View/download PDF
10. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
- Author
-
Kristensen, Søren L., primary, Jhund, Pardeep S., additional, Køber, Lars, additional, Preiss, David, additional, Kjekshus, John, additional, McKelvie, Robert S., additional, Zile, Michael R., additional, Anand, Inder S., additional, Wikstrand, John, additional, Wedel, Hans, additional, Komajda, Michel, additional, Carson, Peter E., additional, Cleland, John G.F., additional, and McMurray, John J.V., additional
- Published
- 2014
- Full Text
- View/download PDF
11. Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox.
- Author
-
Butt JH, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Gustafsson F, Kristensen SL, Bruun NE, Eiskjær H, Brandes A, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Schou M, Pehrson S, Packer M, McMurray JJV, and Køber L
- Abstract
Aims: Although body mass index (BMI) is the most commonly used anthropometric measure to assess adiposity, alternative indices such as the waist-to-height ratio may better reflect the location and amount of ectopic fat as well as the weight of the skeleton., Methods and Results: The prognostic value of several alternative anthropometric measures was compared with that of BMI in 1116 patients with non-ischaemic heart failure with reduced ejection fraction (HFrEF) enrolled in DANISH. The association between anthropometric measures and all-cause death was adjusted for prognostic variables, including natriuretic peptides. Median follow-up was 9.5 years (25th-75th percentile, 7.9-10.9). Compared to patients with a BMI 18.5-24.9 kg/m
2 (n = 363), those with a BMI ≥25 kg/m2 had a higher risk of all-cause and cardiovascular death, although this association was only statistically significant for a BMI ≥35 kg/m2 (n = 91) (all-cause death: hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.28-2.48; cardiovascular death: HR 2.46, 95% CI 1.69-3.58). Compared to a BMI 18.5-24.9 kg/m2 , a BMI <18.5 kg/m2 (n = 24) was associated with a numerically, but not a significantly, higher risk of all-cause and cardiovascular death. Greater waist-to-height ratio (as an exemplar of indices not incorporating weight) was also associated with a higher risk of all-cause and cardiovascular death (HR for the highest vs. the lowest quintile: all-cause death: HR 2.11, 95% CI 1.53-2.92; cardiovascular death: HR 2.17, 95% CI 1.49-3.15)., Conclusion: In patients with non-ischaemic HFrEF, there was a clear association between greater adiposity and higher long-term mortality., Clinical Trial Registration: ClinicalTrials.gov NCT00542945., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)- Published
- 2024
- Full Text
- View/download PDF
12. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
- Author
-
Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, and McMurray JJV
- Subjects
- Aged, Biomarkers blood, Diabetes Mellitus, Type 2 blood, Europe epidemiology, Female, Heart Failure complications, Heart Failure epidemiology, Humans, Male, Morbidity trends, Prognosis, Prospective Studies, Risk Factors, Survival Rate trends, Diabetes Mellitus, Type 2 complications, Heart Failure blood, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Stroke Volume physiology, Troponin T blood
- Abstract
Aims: We examined the prognostic importance of N-terminal pro B-type natriuretic peptide (NT-proBNP) and troponin T (TnT) in heart failure patients with and without diabetes., Methods and Results: We measured NT-proBNP and TnT in the biomarker substudy of the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Of 1907 patients, 759 (40%) had diabetes. Median TnT in patients with diabetes was 18 (interquartile range 11-27) ng/L and 13 (9-21) ng/L in those without (P < 0.001). The TnT frequency-distribution curve was shifted to the right in patients with diabetes, compared to those without diabetes. By contrast, NT-proBNP did not differ between patients with and without diabetes. Diabetes and each biomarker were predictive of worse outcomes. Thus, patients with diabetes, an elevated TnT and a NT-proBNP level in the highest tertile (9% of all patients) had an absolute risk of cardiovascular death or heart failure hospitalization of 265 per 1000 person-years, compared to a rate of 42 per 1000 person-years in those without diabetes, a TnT < 18 ng/L and a NT-proBNP in the lowest tertile (16% of all patients). TnT remained an independent predictor of adverse outcomes in multivariable analyses including NT-proBNP., Conclusion: TnT is elevated to a greater extent in heart failure patients with diabetes compared to those without (whereas NT-proBNP is not). TnT and NT-proBNP are additive in predicting risk and when combined help identify diabetes patients at extremely high absolute risk., (© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2019
- Full Text
- View/download PDF
13. Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
- Author
-
Kristensen SL, Rørth R, Jhund PS, Shen L, Lee MMY, Petrie MC, Køber L, and McMurray JJV
- Subjects
- Diabetic Angiopathies epidemiology, Diabetic Angiopathies physiopathology, Double-Blind Method, Female, Follow-Up Studies, Heart Failure complications, Heart Failure physiopathology, Humans, Incidence, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Survival Rate trends, Time Factors, United Kingdom epidemiology, Adrenergic beta-Antagonists therapeutic use, Diabetic Angiopathies complications, Heart Failure drug therapy, Stroke Volume physiology
- Abstract
Aims: The role of microvascular complications in the risk conferred by diabetes in heart failure with reduced ejection fraction (HFrEF) is unknown., Methods and Results: We studied 2707 HFrEF patients in the Beta-blocker Evaluation of Survival Trial (BEST), stratified into three groups: no diabetes and diabetes without or with microvascular complications (neuropathy, nephropathy, or retinopathy). The risks of the composite of cardiovascular death or heart failure hospitalization, and all-cause death, were studied using Cox regression analyses adjusted for other prognostic variables. Overall, 964 (36%) patients had diabetes, of which 313 (32%) had microvascular complications. Patients with microvascular complications had more severe symptoms (New York Heart Association class IV 12% vs. 9% diabetes with no complications and 7% no diabetes), and worse quality of life (Minnesota Living with Heart Failure median score 60 vs. 54 and 51 points). In patients with diabetes and complications, the rate of the composite outcome was 50 per 100 person-years of follow-up (compared with 34 and 29 in those with diabetes and no microvascular complications and participants without diabetes, respectively). Compared to patients without diabetes, the adjusted hazard ratio (HR) for the composite outcome was 1.44 [95% confidence interval (CI) 1.22-1.70] and 1.18 (95% CI 1.03-1.35) for patients with diabetes with and without complications, respectively. The risk of all-cause mortality was similarly elevated: adjusted HR 1.42 (95% CI 1.16-1.74) and 1.20 (95% CI 1.01-1.42), respectively., Conclusion: In HFrEF, diabetes with microvascular complications is associated with worse symptoms and outcomes than diabetes without microvascular complications. Prevention of microvascular complications has the potential to improve HFrEF outcomes., (© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.)
- Published
- 2018
- Full Text
- View/download PDF
14. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
- Author
-
Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, and McMurray JJV
- Subjects
- Angiotensin Receptor Antagonists therapeutic use, Biomarkers blood, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Glomerular Filtration Rate drug effects, Heart Failure blood, Heart Failure physiopathology, Humans, Male, Middle Aged, Neprilysin, Prognosis, Treatment Outcome, Valsartan, Aminobutyrates therapeutic use, Heart Failure drug therapy, Stroke Volume drug effects, Tetrazoles therapeutic use, Uric Acid blood
- Abstract
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF., Methods and Results: The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1-Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline over 12 months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6 mg/dL) compared with Q1 (<5.4 mg/dL) were younger (62.8 vs. 64.2 years), more often male (88.7% vs. 63.1%), had lower systolic blood pressure (119 vs. 123 mmHg), lower eGFR (57.4 vs. 76.6 mL/min/1.73 m
2 ), and greater diuretic use. Higher SUA was associated with a higher risk of the primary outcome (adjusted hazard ratios) Q5 vs. Q1 = 1.28 [95% confidence intervals (1.09-1.50), P = 0.003], cardiovascular death [1.44 (1.11-1.77), P = 0.001], HF hospitalization [1.37 (1.11-1.70), P = 0.004], and all-cause mortality [1.36 (1.13-1.64), P = 0.001]. Compared with enalapril, sacubitril/valsartan reduced SUA by 0.24 (0.17-0.32) mg/dL over 12 months (P < 0.0001). Sacubitril/valsartan improved outcomes, irrespective of SUA concentration., Conclusion: Serum uric acid concentration was an independent predictor of worse outcomes after multivariable adjustment in patients with HFrEF. Compared with enalapril, sacubitril/valsartan reduced SUA and improved outcomes irrespective of SUA., (© 2017 The Authors. European Journal of Heart Failure published by John Wiley © Sons Ltd on behalf of European Society of Cardiology.)- Published
- 2018
- Full Text
- View/download PDF
15. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
- Author
-
Rørth R, Fosbøl EL, Mogensen UM, Kragholm K, Numé AK, Gislason GH, Jhund PS, Petrie MC, McMurray JJV, Torp-Pedersen C, Køber L, and Kristensen SL
- Subjects
- Adolescent, Adult, Cause of Death trends, Comorbidity trends, Denmark epidemiology, Female, Follow-Up Studies, Heart Failure therapy, Hospitalization statistics & numerical data, Humans, Incidence, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Factors, Survival Rate trends, Time Factors, Young Adult, Diabetes Mellitus epidemiology, Employment, Heart Failure epidemiology, Patient Readmission trends, Pulmonary Disease, Chronic Obstructive epidemiology, Registries, Risk Assessment methods
- Abstract
Aims: Employment status at time of first heart failure (HF) hospitalization may be an indicator of both self-perceived and objective health status. In this study, we examined the association between employment status and the risk of all-cause mortality and recurrent HF hospitalization in a nationwide cohort of patients with HF., Methods and Results: We identified all patients of working age (18-60 years) with a first HF hospitalization in the period 1997-2015 in Denmark, categorized according to whether or not they were part of the workforce at time of the index admission. The primary outcome was death from any cause and the secondary outcome was readmission for HF. Cumulative incidence curves, binomial regression and Cox regression models were used to assess outcomes. Of 25 571 patients with a first hospitalization for HF, 15 428 (60%) were part of the workforce at baseline. Patients in the workforce were significantly younger (53 vs. 55 years) more likely to be male (75% vs 64%) and less likely to have diabetes (13% vs 22%) and chronic obstructive pulmonary disease (5% vs 10%) (all P < 0.0001). Not being part of the workforce was associated with a significantly higher risk of death [hazard ratio (HR) 1.59; 95% confidence interval (CI) 1.50-1.68] and rehospitalization for HF (HR 1.09; 95% CI 1.05-1.14), in analyses adjusted for age, sex, co-morbidities, education level, calendar time, and duration of first HF hospitalization., Conclusion: Not being part of the workforce at time of first HF hospitalization was independently associated with increased mortality and recurrent HF hospitalization., (© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.)
- Published
- 2018
- Full Text
- View/download PDF
16. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
- Author
-
Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q, Chiang Y, Jhund PS, Abraham WT, Dickstein K, McMurray JJV, and Køber L
- Subjects
- Angiotensin-Converting Enzyme Inhibitors administration & dosage, Antihypertensive Agents administration & dosage, Cause of Death trends, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Europe epidemiology, Female, Follow-Up Studies, Heart Failure complications, Heart Failure mortality, Humans, Male, Middle Aged, Prospective Studies, Stroke Volume, Survival Rate trends, Amides administration & dosage, Diabetes Mellitus drug therapy, Enalapril administration & dosage, Fumarates administration & dosage, Heart Failure drug therapy
- Abstract
Aims: Because of concerns about the safety of aliskiren in patients with diabetes, study treatment was stopped prematurely in the Aliskiren Trial of Minimizing OutcomeS for Patients with HEart failuRE (ATMOSPHERE). We examined outcomes and treatment effect in these patients compared with those without diabetes., Methods and Results: ATMOSPHERE included 7016 patients with heart failure and a reduced ejection fraction (HFrEF) randomly assigned to enalapril plus aliskiren, aliskiren alone, or enalapril. At baseline, 1944 (27.7%) patients had diabetes. Median follow-up was shorter in patients with diabetes compared with those without (24 months vs. 46 months). Among patients with diabetes, the primary endpoint of cardiovascular death or hospitalization for heart failure occurred in 216 patients (33.1%) in the enalapril group (reference), 172 (27.4%) in the aliskiren group [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.67-1.00; P = 0.053], and 196 (29.5%) in the combination group (HR 0.86, 95% CI 0.71-1.04; P = 0.13). The effects of the treatments studied did not differ significantly compared with patients without diabetes. In patients with diabetes, aliskiren monotherapy was associated with a lower risk of symptomatic hypotension compared to enalapril [42 (6.7%) vs. 65 (10.0%); P = 0.04], whereas other adverse events were generally balanced between the three groups., Conclusion: In patients with HFrEF and diabetes, there was no signal of harm and a trend towards benefit when direct renin inhibition monotherapy was compared with an angiotensin-converting enzyme inhibitor, whereas combined aliskiren and enalapril treatment led to more adverse events with no improvement in outcomes. Treatment effects did not differ in patients with diabetes compared with those without. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00853658., (© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.)
- Published
- 2018
- Full Text
- View/download PDF
17. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
- Author
-
Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, and McMurray JJ
- Subjects
- Aged, Amnesia epidemiology, Biphenyl Compounds, Confusion epidemiology, Delirium epidemiology, Disorders of Excessive Somnolence epidemiology, Drug Combinations, Female, Heart Failure physiopathology, Humans, Male, Middle Aged, Neprilysin antagonists & inhibitors, Proportional Hazards Models, Stroke Volume, Valsartan, Aminobutyrates therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Dementia epidemiology, Enalapril therapeutic use, Heart Failure drug therapy, Tetrazoles therapeutic use
- Abstract
Aims: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril. As neprilysin is also one of many enzymes clearing amyloid-β peptides from the brain, there is a theoretical concern about the long-term effects of sacubitril/valsartan on cognition. Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in the context of other recently conducted HFrEF trials., Methods and Results: In PARADIGM-HF, patients with symptomatic HFrEF were randomized to sacubitril/valsartan 97/103 mg b.i.d. or enalapril 10 mg b.i.d. in a 1:1 ratio. We systematically searched AE reports, coded using the Medical Dictionary for Regulatory Activities (MedDRA), using Standardized MedDRA Queries (SMQs) with 'broad' and 'narrow' preferred terms related to dementia. In PARADIGM-HF, 8399 patients aged 18-96 years were randomized and followed for a median of 2.25 years (up to 4.3 years). The narrow SMQ search identified 27 dementia-related AEs: 15 (0.36%) on enalapril and 12 (0.29%) on sacubitril/valsartan [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.33-1.59]. The broad search identified 97 (2.30%) and 104 (2.48%) AEs (HR 1.01, 95% CI 0.75-1.37), respectively. The rates of dementia-related AEs in both treatment groups in PARADIGM-HF were similar to those in three other recent trials in HFrEF., Conclusion: We found no evidence that sacubitril/valsartan, compared with enalapril, increased dementia-related AEs, although longer follow-up may be necessary to detect such a signal and more sensitive tools are needed to detect lesser degrees of cognitive impairment. Further studies to address this question are warranted., (© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2017
- Full Text
- View/download PDF
18. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
- Author
-
Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, and McMurray JJ
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Heart Failure physiopathology, Humans, Male, Middle Aged, Heart Failure diagnosis, Hospitalization statistics & numerical data, Myocardial Infarction diagnosis, Patient Outcome Assessment, Stroke diagnosis, Stroke Volume physiology
- Abstract
Aims: To investigate the prognostic significance of hospitalization for worsening heart failure (WHF), myocardial infarction (MI), and stroke in patients with chronic heart failure (HF)., Methods and Results: We studied 5011 patients with HF and reduced EF (HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF (HF-PEF) in the I-Preserve trial. Adjusted hazard ratios (HRs) for death were estimated for 0-30 days and ≥31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality ≤30 days after an event was: WHF 7.21 [95% confidence interval (CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality ≤30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29)., Conclusions: In patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event., (© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.